Clinical trial · people

VIP: peak flow rose 26 l/min in severe asthma, less than salbutamol

Checked against the paper Clinical trialPublished by PepVault

The takeaway

In this small hospital study, VIP given into a vein opened the airways in severe asthma, but less than salbutamol did.

Kind
Clinical trial
Studied in
People
Published
1986
Journal
Peptides

What they tested

The team tested whether VIP given into a vein opens the airways in people with severe asthma, and how it compares with the standard asthma drug salbutamol.

How the study was done

A small clinical trial made of two studies, each in a small group of hospital in-patients who were recovering from a severe asthma attack. VIP was given as an intravenous drip (into a vein) at 6 pmol/kg/min and compared with salbutamol at 5 mcg/min, and VIP was also tested after pretreatment with nebulized ipratropium bromide, another airway drug.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking VIP? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

After 30 minutes of the VIP drip, peak expiratory flow rate (PEFR, how fast a person can blow air out) rose by 26 +/- 9 l/min, a significant change (p less than 0.01). Salbutamol produced a rise of 39 +/- 19 l/min. When patients first had ipratropium bromide, VIP still raised peak flow by 25 l/min (p less than 0.02). The authors concluded that VIP widens the airways in severe asthma but less than standard medicine, and that reflex mechanisms are unlikely to explain its effect.

What it doesn’t show

The groups were small and the effect was measured over a short drip. It tested only intravenous VIP in hospital patients recovering from an attack, so it says nothing about other routes, longer use or milder asthma.

The paper

Morice and Sever Vasoactive intestinal peptide as a bronchodilator in severe asthma. Peptides. 1986.

The compound

More studies on VIP

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking VIP? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo